Diabetic Neuropathy Market, By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy), By Treatment Type (Drugs, Analgesic, Antidepressants, Anticonvulsant Drugs, Radiotherapy and Physiotherapy), By Distribution Channel (Hospitals, Clinics, Retail Pharmacy, Online Pharmacy), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Trends, Analysis and Forecast till 2030

Diabetic Neuropathy Market accounted for US$ 4.22 billion in 2020 and is estimated to be US$ 9.87 billion by 2030 and is anticipated to register a CAGR of 8.90%.

The damage caused to nerves due to diabetes which leads to numbness and pain often felt in the lower body part like legs and feet is known as diabetic neuropathy. This is a common complication in both the types of diabetes i.e. type1 and type 2 which in turn affects the nerves of thigh, wrist, chest, back, etc. The factors that cause nerve damage in diabetes condition includes kidney disease, poor blood sugar control, excess weight, smoking, and length of time to have diabetes. However, anyone who has diabetes can develop neuropathy. Some symptoms of diabetic neuropathy are pain, tingling, numbness, and loss of feeling in the hands, arms, feet, and legs. The treatment options for diabetic neuropathy include drugs, physiotherapy and radiotherapy. 

                                                                                   Increasing number of obesity

Increasing number of obesity overall the globe is a major factor that drives the global diabetic neuropathy market. Further, increasing number of cardiovascular disease also supports the growth of target market. For instance, according to World Health Organization, in May 2017, An estimated 17.9 million people died from cardiovascular diseases in 2016, representing 31% of all global deaths. The factors such as changing lifestyle and urbanization leads to change in genetic composition of the body resulting to obesity.

                                                                                   Rising government initiatives

The rising government initiatives in order to reduce diabetic related disease supports the global diabetic neuropathy market. For instance, according to World Health Organization, on October 2018, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. The global prevalence of diabetes among adults over 18 years has risen from 4.7% in 1980 to 8.5% in 2014. Further, some private health organizations and non- profitable organization also provide funds for research activities on neuropathy. In addition, several Non-governmental organizations (NGOs) are taking some steps to control diabetes and withdraw symptoms of diabetic neuropathy which has thrived the global diabetic neuropathy market. However, the cost of the treatment is likely to hinder the growth of the target market. The market for diabetic neuropathy has been under continuous evolution for the development of the generic drugs, specialty drugs, and drugs to treat pain associated with the disorder, which is the major trend in the global diabetic neuropathy market.

Diabetic Neuropathy Market is segmented based on disorder type, treatment type, distribution channel and region.

On the basis of disorder type, global market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy. On the basis of treatment type, the global market is sub divided into Drugs, Analgesic, Antidepressants, Anticonvulsant Drugs, Radiotherapy and Physiotherapy. On the basis of distribution channel, the global market is segmented into Hospitals, Clinics, Retail Pharmacy, Online Pharmacy.

Regional Insights:

For detailed understanding of market dynamics, the global diabetic neuropathy market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the global market. In 2018, it has been observed that North America is the largest market for diabetic neuropathy followed by other regions. This is due to the rise in research activities and increasing awareness among people about diabetes and its complications. Further, the Asia Pacific is also expected to show significant growth due to increasing number of patients with diabetes and improving healthcare infrastructure in the region.

Diabetic Neuropathy Market, By Disorder Type:

• Peripheral Neuropathy
• Focal Neuropathy
• Proximal Neuropathy
• Autonomic Neuropathy

Diabetic Neuropathy Market, By Treatment Type:

• Drugs
• Physiotherapy
• Radiotherapy
• Anticonvulsant Drugs
• Antidepressants
• Analgesic

Diabetic Neuropathy Market, By Distribution Channel:

• Hospitals
• Online Pharmacy
• Retail Pharmacy
• Clinics

Diabetic Neuropathy Market, By Region:

• North America
  • Middle East & Africa
    • Middle East & Africa Diabetic Neuropathy Market, By Disorder Type
    • Middle East & Africa Diabetic Neuropathy Market, By Treatment Type
    • Middle East & Africa Diabetic Neuropathy Market, By Distribution Channel
    • Middle East & Africa Diabetic Neuropathy Market, By Country
      • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • Latin America Diabetic Neuropathy Market, By Disorder Type
    • Latin America Diabetic Neuropathy Market, By Treatment Type
    • Latin America Diabetic Neuropathy Market, By Distribution Channel
    • Latin America Diabetic Neuropathy Market, By Country
      • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • Asia Pacific Diabetic Neuropathy Market, By Disorder Type
    • Asia Pacific Diabetic Neuropathy Market, By Treatment Type
    • Asia Pacific Diabetic Neuropathy Market, By Distribution Channel
    • Asia Pacific Diabetic Neuropathy Market, By Country
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • Europe Diabetic Neuropathy Market, By Disorder Type
    • Europe Diabetic Neuropathy Market, By Treatment Type
    • Europe Diabetic Neuropathy Market, By Distribution Channel
    • Europe Diabetic Neuropathy Market, By Country
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • North America Diabetic Neuropathy Market, By Disorder Type
  • North America Diabetic Neuropathy Market, By Treatment Type
  • North America Diabetic Neuropathy Market, By Distribution Channel
  • North America Diabetic Neuropathy Market, By Country
    • U.S.
    • Canada

Some of the prominent players operating in the global diabetic neuropathy market include Pfizer Inc., Janssen Pharmaceuticals, Inc., Eli Lilly and Company, ACTAVIS, Cephalon, Inc., MEDA Pharma GmbH & Co. KG, GlaxoSmithKline, NeuroMetrix, Inc, Lupin limited and Glenmark Pharmaceuticals Ltd. Technological advancements in the product as well as in manufacturing process and product launches are some trends which are witnessed in the global diabetic neuropathy market. For instance, in December 2017, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes. Further, in June 2019, Janssen Pharmaceuticals stated that INVOKANA (canagliflozin) significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes and chronic kidney disease in new credence analysis.

• Pfizer Inc.
• Janssen Pharmaceuticals, Inc.,
• Eli Lilly and Company
• ACTAVIS
• Cephalon, Inc.
• MEDA Pharma GmbH & Co. KG
• GlaxoSmithKline
• NeuroMetrix, Inc
• Lupin limited
• Glenmark Pharmaceuticals Ltd.